Guardant Health said today that its Guardant360 liquid biopsy test will be covered by health plans associated with technology assessment firm EviCore beginning this summer.
As a result, the test will have become a covered benefit for approximately 150 million people in total.
The new decision by EviCore will make the test covered for its health plan members as medically necessary to assist in selecting therapy for patients with advanced lung cancer, beginning July 1. Guardant said the new decision followed the University of Pennsylvania prospective study publication in JAMA Oncology, which evaluated the use of Guardant360 to guide the first-line treatment of patients with advanced lung cancer. Investigators in that study found that Guardant360 has sensitivity and detection rates comparable to tissue testing, and that patients responded to the treatment selected based on Guardant360 results.